Table 2.
Echocardiographic measurements
| Sham + Veh | Sham + TNFR1 shRNA | Sham + Con shRNA | HF + Veh | HF + TNFR1 shRNA | HF + Con shRNA | |
|---|---|---|---|---|---|---|
| Variables at baseline | ||||||
| LVEDV, ml | 0.46 ± 0.03 | 0.47 ± 0.02 | 0.46 ± 0.03 | 0.75 ± 0.04* | 0.79 ± 0.04* | 0.79 ± 0.03* |
| LV volume/mass, µl/mg | 0.54 ± 0.04 | 0.57 ± 0.03 | 0.57 ± 0.02 | 1.22 ± 0.08* | 1.26 ± 0.09* | 1.24 ± 0.08* |
| LVEF | 0.73 ± 0.03 | 0.71 ± 0.04 | 0.70 ± 0.03 | 0.36 ± 0.04* | 0.33 ± 0.03* | 0.31 ± 0.03* |
| %IZ | 42 ± 5* | 43 ± 2* | 43 ± 2* | |||
| Variables at week 4 | ||||||
| LVEDV, ml | 0.51 ± 0.03 | 0.49 ± 0.01 | 0.51 ± 0.02 | 1.13 ± 0.11*† | 1.00 ± 0.10* | 1.12 ± 0.10*† |
| LV volume/mass, µl/mg | 0.64 ± 0.04 | 0.61 ± 0.03 | 0.60 ± 0.03 | 1.47 ± 0.9* | 1.42 ± 0.12* | 1.48 ± 0.06* |
| LVEF | 0.74 ± 0.04 | 0.74 ± 0.03 | 0.75 ± 0.03 | 0.28 ± 0.03* | 0.32 ± 0.03* | 0.29 ± 0.02* |
| %IZ | 44 ± 2* | 42 ± 2* | 44 ± 2* |
Values are expressed as means ± SE; n = 13 animals/group. Sham, sham operation; Veh, vehicle; Con, control; HF, heart failure; LVEDV, left ventricular (LV) end-diastolic volume; LVEF, LV ejection fraction; %IZ, ischemic zone as a percentage of LV circumference. Data were analyzed with two-way ANOVA followed by multiple-comparison tests [LVEDV: time effect, F(1, 144) = 30, P < 0.0001, and group effect, F(5, 144) = 39, P < 0.0001; LV volume/mass: time effect, F(1, 144) = 12, P = 0.0008, and group effect, F(5, 144) = 76, P < 0.0001; LVEF: time effect, F(1, 144) = 0.13, P = 0.72, and group effect, F(5, 144) = 115, P < 0.0001; %IZ: time effect, F(1, 144) = 0.004, P = 0.95, and group effect, F(5, 144) = 532, P < 0.0001].
P < 0.05 vs. the Sham + Veh group at the same week;
P < 0.05 vs. HF + Veh or HF + Con shRNA groups at 4 wk vs. 24 h.